Eiger Biopharmaceuticals (EIGR) Earns News Impact Score of 0.07

News stories about Eiger Biopharmaceuticals (NASDAQ:EIGR) have trended somewhat positive on Monday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Eiger Biopharmaceuticals earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 47.86099497644 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:

Eiger Biopharmaceuticals (NASDAQ EIGR) opened at $13.15 on Monday. The company has a market capitalization of $140.97, a P/E ratio of -2.48 and a beta of 2.54. The company has a current ratio of 5.78, a quick ratio of 5.78 and a debt-to-equity ratio of 1.19. Eiger Biopharmaceuticals has a 52-week low of $6.10 and a 52-week high of $13.95.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last released its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.28) by $0.18. analysts predict that Eiger Biopharmaceuticals will post -4.59 earnings per share for the current fiscal year.

EIGR has been the topic of several research analyst reports. ValuEngine raised Eiger Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Oppenheimer reaffirmed a “buy” rating and issued a $34.00 price objective on shares of Eiger Biopharmaceuticals in a research note on Monday, September 25th. Zacks Investment Research raised Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research note on Monday, October 16th. Roth Capital initiated coverage on Eiger Biopharmaceuticals in a research report on Thursday, October 19th. They set a “buy” rating and a $35.00 price target on the stock. Finally, Wedbush reissued a “buy” rating on shares of Eiger Biopharmaceuticals in a research report on Wednesday, October 25th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $30.43.

ILLEGAL ACTIVITY WARNING: “Eiger Biopharmaceuticals (EIGR) Earns News Impact Score of 0.07” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.com-unik.info/2017/12/25/eiger-biopharmaceuticals-eigr-earns-news-impact-score-of-0-07.html.

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Insider Buying and Selling by Quarter for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit